Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05630547 (ClinicalTrials.gov)	December 19, 2022	7/11/2022	A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis	A Phase 2 Double-blind, Randomized, Placebo-controlled Study Evaluating the Effect of SAR443820 on Serum Neurofilament Levels in Participants With Multiple Sclerosis, Followed by an Open-label Long-term Extension Period	Multiple Sclerosis	Drug: SAR443820;Other: Placebo	Sanofi	NULL	Recruiting	18 Years	60 Years	All	168	Phase 2	Belgium;Canada;China;France;Italy;Poland;Spain
2	EUCTR2022-000049-34-ES (EUCTR)	21/07/2022	22/07/2022	Phase 2 study of SAR443820 in participants with multiple sclerosis (MS)	A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long-term extension period	Multiple sclerosis MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: SAR443820 INN or Proposed INN: SAR443820 Other descriptive name: RA15804589, C19061501-F, DNL788, DN2489, DN0002489	Sanofi-aventis recherche & développement	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	280	Phase 2	France;United States;Czechia;Canada;Belgium;Poland;Spain;Germany;Italy;China
3	NCT04982991 (ClinicalTrials.gov)	August 5, 2021	20/7/2021	Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants	A Phase 1, Open-label, 3-treatment Period, 1-sequence, Cross-over Study of the Pharmacokinetics, Safety and Tolerability After Single Ascending Oral Doses of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants.	Multiple Sclerosis Healthy Subjects	Drug: RIPK1 inhibitor	Sanofi	NULL	Completed	20 Years	55 Years	All	14	Phase 1	United Kingdom